)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
GVS
GVS (GVS) investor relations material
GVS Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary11 Nov, 2026
Executive summary
9M 2026 revenue was €329.9m, up 6.4% at constant FX; Q3 revenue was €114.8m, with organic growth accelerating to 13.2%.
Adjusted EBITDA rose 9.0% to €85.8m, with a 26.0% margin; adjusted net profit excluding FX effects was €37.5m, up 3.3%.
Net financial position was €253.5m at 30 September 2026, with leverage of 2.2x.
Financial highlights
Revenue increased from €315.6m to €329.9m; 9M organic growth was 6.4%, comprising volume growth of 3.9% and net price growth of 2.6%.
Adjusted EBITDA rose from €78.7m to €85.8m; margin expanded from 24.9% to 26.0%, up 106 bps.
Adjusted EBIT was €58.8m, or 17.8% of sales, versus €55.7m and 17.6%; adjusted D&A increased to €26.2m from €22.6m.
Adjusted net profit excluding FX effects was €37.5m, with an 11.4% margin, versus €36.3m and 11.5%; including FX effects, adjusted net profit was €41.8m versus €20.7m.
Reported net profit was €33.7m versus €9.0m; basic and diluted EPS were both €0.18 versus €0.05.
Outlook and guidance
FY 2026 guidance confirmed: mid-single-digit revenue growth at constant FX and adjusted EBITDA margin expansion of 50–100 bps versus 2025.
FY 2026 leverage is expected near 2.0x; Q4 sales of €113m–€114m would support the 5% organic growth target.
H2 adjusted EBITDA is forecast at €60m–€61m versus €55m in H1; Q4 revenue is expected broadly in line with Q3.
Q4 working-capital plans include reducing inventory and receivables by ~€10m each; year-end net financial position is expected near €225m.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from GVS
- Sales and adjusted EBITDA advanced as margins recovered and leverage declined.GVS
H2 2023 - Raised guidance targets 5% organic growth, 27% EBITDA margin, and 1.0x leverage by 2028.GVSInvestor update
- Revenue and EBITDA margin rose, with strong net profit and confirmed growth guidance.GVSQ2 2026
- Q1 2026: Revenue €105M, margin up, Healthcare strong, and share buyback announced.GVSQ1 2026
- Adjusted EBITDA margin rose to 24.9% as net debt increased from M&A and buybacks.GVSQ3 2025
- Record profitability and margin gains in H1 2025, with strong outlook for H2.GVSQ2 2025
- Revenue up 3.7%, EBITDA margin 24.3%, leverage 2.30x, led by Healthcare & Safety growth.GVSQ3 2024
- H1 2024 revenue and margins rose, guidance was raised, and Health & Safety led growth.GVSH1 2024
- Q1 2025 revenue rose 3.2% to €107.2M, with margin gains and Haemonetics integration.GVSQ1 2025
Next GVS earnings date
Q4 202625 Mar, 2027
GVS
Next GVS earnings date
Q4 202625 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
GVS S.p.A. is an Italian company specializing in the development and manufacturing of filtration solutions. Established in 1979, the company serves a variety of industries, including healthcare and life sciences, energy and mobility, and health and safety. GVS's product offerings encompass seven main lines: Healthcare, Laboratory, Mobility, Air Safety, Appliance, Personal Safety, and Membranes, providing a broad range of customizable filtration products and services tailored to specific market needs. The company is headquartered in Zola Predosa, Italy, and its shares are listed on the Borsa Italiana.